Genes, Development and Disease Group, F-BBVA Cancer Cell Biology programme, National Cancer Research Centre (CNIO), Madrid, Spain.
Oncogene. 2011 Mar 31;30(13):1506-17. doi: 10.1038/onc.2010.542. Epub 2010 Nov 29.
Mice lacking c-fos develop osteopetrosis due to a block in osteoclast differentiation. Carboxy-terminal phosphorylation of Fos on serine 374 by ERK1/2 and serine 362 by RSK1/2 regulates Fos stability and transactivation potential in vitro. To assess the physiological relevance of Fos phosphorylation in vivo, serine 362 and/or serine 374 was replaced by alanine (Fos362A, Fos374A and FosAA) or by phospho-mimetic aspartic acid (FosDD). Homozygous mutants were healthy and skeletogenesis was largely unaffected. Fos C-terminal phosphorylation, predominantly on serine 374, was found important for osteoclast differentiation in vitro and affected lipopolysaccharide (LPS)-induced cytokine response in vitro and in vivo. Importantly, skin papilloma development was delayed in FosAA, Fos362A and Rsk2-deficient mice, accelerated in FosDD mice and unaffected in Fos374A mutants. Furthermore, the related Fos protein and putative RSK2 target Fra1 failed to substitute for Fos in papilloma development. This indicates that phosphorylation of serines 362 and 374 exerts context-dependent roles in modulating Fos activity in vivo. Inhibition of Fos C-terminal phosphorylation on serine 362 by targeting RSK2 might be of therapeutic relevance for skin tumours.
由于破骨细胞分化受阻,缺乏 c-fos 的小鼠发生骨质硬化症。ERK1/2 将 Fos 的丝氨酸 374 羧基末端磷酸化,RSK1/2 将丝氨酸 362 磷酸化,调节体外 Fos 的稳定性和转录激活潜能。为了评估体内 Fos 磷酸化的生理相关性,丝氨酸 362 和/或丝氨酸 374 被丙氨酸(Fos362A、Fos374A 和 FosAA)或磷酸模拟天冬氨酸(FosDD)取代。纯合突变体健康,骨骼发生基本不受影响。发现 Fos C 末端磷酸化,主要在丝氨酸 374 上,对体外破骨细胞分化很重要,并影响脂多糖(LPS)诱导的体外和体内细胞因子反应。重要的是,FosAA、Fos362A 和 Rsk2 缺陷小鼠的皮肤乳头状瘤发育延迟,FosDD 小鼠的加速,而 Fos374A 突变体不受影响。此外,相关的 Fos 蛋白和推定的 RSK2 靶 Fra1 未能替代 Fos 在乳头状瘤发育中的作用。这表明丝氨酸 362 和 374 的磷酸化在体内调节 Fos 活性中发挥了上下文相关的作用。通过靶向 RSK2 抑制 Fos C 末端丝氨酸 362 的磷酸化可能对皮肤肿瘤具有治疗意义。